• Cisplatin Mechanisms & Strategy: Next-Gen Translational Insi

  2026-05-25

  This article delivers an integrative thought-leadership perspective on cisplatin (CDDP), illuminating mechanistic underpinnings, experimental best practices, and translational strategies for overcoming chemotherapy resistance. Drawing on recent evidence—including gefitinib combination approaches in NSCLC—and leveraging APExBIO’s high-quality cisplatin (SKU: A8321), we offer actionable guidance for translational researchers seeking to advance the field beyond conventional protocols.

• Astrocytic GAT-3 Modulates Synaptic Transmission in Dentate

  2026-05-25

  This study reveals that astrocytic GAT-3 critically regulates synaptic transmission and memory formation in the dentate gyrus by modulating astrocytic calcium signaling and neurotransmitter release. The findings advance our molecular understanding of hippocampal cognitive mechanisms and suggest new directions for targeting astrocyte-mediated processes in cognitive disorders.

• Bone Transport Accelerates Diabetic Foot Ulcer Healing via T

  2026-05-24

  This study demonstrates that bone transport surgery promotes diabetic foot ulcer healing by activating TGF-β1-mediated angiogenic and immune pathways. The findings define a mechanistic link between osteogenesis, angiogenesis, and immunomodulation, highlighting the TGF-β1/TGFBR1 axis as a promising target for chronic wound therapy.

• LY2109761: Advancing TGF-β Pathway Modulation in Translation

  2026-05-23

  This thought-leadership article unveils the strategic potential of LY2109761, a potent TGF-β receptor type I and II dual inhibitor, for translational oncology and fibrotic disease research. Integrating mechanistic insights, recent evidence, and practical guidance, it equips researchers to exploit Smad2/3 signaling blockade for breakthroughs in tumor biology, radiosensitization, and fibrosis, while contextualizing LY2109761 amid the evolving competitive landscape.

• SIRT1-Regulated Ran Lactylation Drives Astrocyte Polarizatio

  2026-05-22

  This study uncovers a novel mechanism linking lactate metabolism to astrocyte polarization following spinal cord injury. By demonstrating that SIRT1-regulated lactylation of Ran at lysine 123 is essential for STAT3-driven astrocyte responses, the findings offer new molecular targets for modulating CNS repair.

• Phase III Trials of Gepotidacin for uUTI: Design and Implica

  2026-05-22

  This article examines the protocol and rationale behind two large, multicenter phase III studies comparing gepotidacin to nitrofurantoin for uncomplicated urinary tract infection (uUTI) in women. The trials represent a pivotal step in evaluating a novel, first-in-class bacterial topoisomerase inhibitor amid rising antibiotic resistance, with design features tailored to current regulatory expectations.

• GSTA1 Drives Glutathione Loss in α-Amanitin Hepatotoxicity

  2026-05-21

  The reference study demonstrates that GSTA1, typically considered a hepatic detoxifier, paradoxically exacerbates α-amanitin-induced liver injury by depleting glutathione and intensifying oxidative stress. This mechanistic insight identifies GSTA1 as a potential therapeutic target and biomarker for acute hepatotoxicity.

• High-Throughput Target Deconvolution for M. tuberculosis DHF

  2026-05-21

  The reference study presents a novel framework integrating high-throughput screening, biophysical profiling, and machine learning to identify mechanisms of action (MoA) for antibacterial compounds, exemplified by the discovery of selective Mycobacterium tuberculosis dihydrofolate reductase (DHFR) inhibitors. This approach bridges the gap between phenotypic and target-based screens, providing actionable insights for antibacterial research and compound development.

• BRCA2 and Nascent Strand Maturation in the Presence of Olapa

  2026-05-20

  A recent study reveals that BRCA2 is essential for the maturation of nascent DNA strands when PARP inhibitors like Olaparib impede DNA replication. These insights clarify the interplay between DNA repair pathways and inform the design of DNA damage response and tumor radiosensitization studies.

• Gepotidacin (GSK2140944): Transformative Tools for Antibacte

  2026-05-20

  Gepotidacin (GSK2140944) empowers researchers to dissect bacterial DNA replication inhibition with precision, enabling robust modeling of antibiotic resistance and novel antibacterial workflows. This guide details protocol enhancements, troubleshooting strategies, and experimental insights tailored to maximize the unique dual-targeting potential of Gepotidacin.

• Gepotidacin (GSK2140944): Applied Protocols in Antibacterial

  2026-05-19

  Gepotidacin (GSK2140944), a first-in-class triazaacenaphthylene antibiotic, transforms antibacterial research with its unique mechanism targeting DNA gyrase and topoisomerase IV—even in fluoroquinolone-resistant strains. This guide delivers actionable protocols, troubleshooting strategies, and insights drawn from recent molecular advances to empower cutting-edge antibiotic resistance research.

• Vincristine Sulfate (A1765) for Reliable Cancer Research Wor

  2026-05-19

  This article delivers scenario-driven guidance for scientists employing Vincristine sulfate (SKU A1765) in cell viability, cytotoxicity, and proliferation assays. We address real laboratory challenges—such as solubility, reproducibility, and data interpretation—by grounding recommendations in primary product data and peer-reviewed literature. Researchers will find validated protocols and clear rationales for selecting Vincristine sulfate in demanding oncology and cell biology workflows.

• Microbiota–Tryptophan–AhR Axis in Ulcerative Colitis Repair

  2026-05-18

  Li et al. (2026) establish that Huangqin decoction (HQD) repairs ulcerative colitis by modulating the gut microbiome to enhance tryptophan metabolism and activate the aryl hydrocarbon receptor (AhR), thereby promoting intestinal stem cell differentiation and mucosal healing. This work clarifies a novel mechanistic axis, providing a foundation for targeted therapeutic strategies in inflammatory bowel disease.

• WAY-100635 in Neuroscience: Precision Tools for 5-HT1A Antag

  2026-05-18

  WAY-100635, a selective 5-HT1A antagonist, transforms serotonin receptor antagonist research with unrivaled specificity and reproducibility. This guide decodes optimized workflows, advanced applications, and troubleshooting strategies, turning complex neuropharmacology into actionable protocols.

• Amyloid Beta-Peptide (1-40) (human): Optimized Experimental

  2026-05-17

  Amyloid Beta-Peptide (1-40) (human) from APExBIO empowers cutting-edge Alzheimer's disease research through its proven fidelity in modeling amyloid fibril formation and neurotoxicity. This article distills advanced workflows, troubleshooting tactics, and the latest mechanistic insights to help researchers achieve reproducible, translational results.

14718 records 1/982 page Next 12345 下5页 Last page